

Amino Acids Interpretation (AAI) Scheme

Administration Office

c/o EMQN CIC, Unit 4, Enterprise House Manchester Science Park Pencroft Way, Manchester, M15 6SE, United Kingdom. Tel: +44 161 757 4952 Fax: +44 161 850 1145 Email: admin@erndim.org

Scientific Advisor

Dr Sabine Scholl-Bürgi Tirol Kliniken Anichstr. 35, A-6020 Innsbruck Austria **Tel:** +43 512 504 23600 **Fax:** +43 512 504 25886 Email: sabine.scholl-buergi@tirol-kliniken.at Scheme Organisers

Administration Office c/o EMQN CIC, Unit 4, Enterprise House Manchester Science Park Pencroft Way, Manchester, M15 6SE, United Kingdom. Tel: +44 161 757 4952 Fax: +44 161 850 1145 Email: admin@erndim.org

2023 Second Round Interim Report (DOC5149)

Version Number¹: 01 Date of issue: 21st December 2023

Please Note:

- This interim report is intended for participants of the ERNDIM AAI scheme. The contents should not be used for any publication without permission of the Scientific Advisor.
- This is an interim report and it includes provisional scores only. All scores are subject to change following
 moderation at the Scientific Advisory Board meeting in autumn of this year. For final scores and performance
 data the ERNDIM AAI Annual Report should be referred to.
- The fact that your laboratory participates in this scheme is not confidential, however, the raw data and
 performance scores are confidential and will only be shared within ERNDIM for the purpose of evaluating your
 laboratories performance, unless ERNDIM is required to disclose performance data by a relevant government
 agency. For details please see the ERNDIM Privacy Policy on <u>www.erndim.org</u>.

1. Results Submission

The deadline for submission of the 2023 second round results was 19th September 2023. Participants were able to view the cases and submit their results using the ERNDIM Formdesk website.

135 laboratories registered for the 2023 AAI scheme, of these 128 labs (95%) submitted results for the second round.

Note: All results must be submitted in English.

2. Scoring System

As for the previous circulations, each of the three aspects, analytical findings, diagnosis, and further tests, were scored equally with a maximum of two points for each category. Plasma amino acid concentrations together with the laboratories reference ranges were provided.

The tables (Table 1-3) show scoring to which the evaluators agreed previously. Scoring was done by two blinded evaluators each (the evaluators were blinded to both, the ERN number and to the scores of the second evaluator). If the scores were not concordant the scheme advisor scored in addition. Further close evaluation based on agreed/revised scoring criteria was used to determine on the final score.

Figure 1 shows an example of scoring



Figure 1: Example of scoring for case 2023.04

¹ If this Report is not Version 1 for this scheme year, go to APPENDIX 2 (page 9) for details of the changes made since the last version of this document.



3. Results of samples and evaluation of reporting

3.1. Case 2023-4: Tyrosinemia type II (homozygous mutation in TAT gene)

3.1.1. Sample Details

The results provided are from seven years old boy with photophobia, eyes pain and visual impairment. The family history is unremarkable, except that the parents are cousins I° grade. The patient did not receive a new-born screening for tyrosinemia in his home country.

The diagnosis of tyrosinemia type II was confirmed by the detection of a homozygous mutation in the *TAT* gene. He received a phenylalanine/tyrosine defined diet after diagnosis. The goal is to keep the tyrosine concentration in the range below 500 µmol/L.

3.1.2. Scoring details

 Table 1: Scoring details for case 2023.04

	interpretation	scores (points)				
findings, abnormalities,	elevated	elevated tyr				
maximum 2 points						
diagnosis, maximum 2 points	tyrosinemia type	2				
	tyrosinemia	1				
further tests (if molecular	organic acids in u	rine (succinylacetone)	1			
genetic recommended specify	molecular geneti	c analyses of TAT	2			
the gene), maximum 2 points	other tyrosinemi	1				
ine gene), maximum z points						

Scores for participating laboratories are in APPENDIX 1 on page 6.

3.1.3. Comments on overall performance

Overall, the interpretation of the analysis results and the diagnosis were very good. The overall performance was 98%.

3.1.4. Best interpretation (scored with 2 points each)

- **Findings:** Grossly elevated concentration of tyrosine, methionine in the normal range.
- **Diagnosis**: Suspicion of tyrosinemia type II (OMIM 276600). Type I is not very probable as the normal pattern of other AA (methionine) speaks against liver involvement. Besides the that fact no crises are reported.
- **Further tests:** Diagnosis should be verified by analysis of organic acids in urine (detection of succinylacetone) and of the *TAT* gene. A low phenylalanine/tyrosine diet should be initiated.



3.2. Case 2023-5: Remethylation defect (CbIC disease)

3.2.1. Sample details

The results provided are from a 55-year-old male patient with pulmonary microangiopathy and renal insufficiency 20 years post renal transplant. Renal insufficiency at 30 years that was not investigated for IEM and has led to a renal transplant.

3.2.2. Scoring details

Table 2: Scoring details for case 2023-5.

	interpretation	scores (points)	
findings, abnormalities,	low (normal)	met	1
maximum 2 points	elevated	homocystine	1
	Primary (IEM) remethy	lation defect	2
diagnosis, maximum 2 points	Secondary (folate, B12	, NO) remethylation	2
	defect	Z	
	organic acids in urine (1	
further tests (if molecular	acylcarnitine profile		Ţ
genetic recommended specify	total homocysteine		1
the gene), maximum 2 points	folate, vitamin B12 cor	ncentration	1
	genes involved in rem	ethylation defects	1
comments	genes involved in rem MMACHC, MMADHC, I	•	HFR,

Scores for <u>participating</u> laboratories are in APPENDIX 1 on page 6. Diagnosis of (mild) hyperhomocysteinaemia was scored only with one point.

3.2.3. Comments on overall performance

The overall performance at 94% was good. Nevertheless, the finding of clearly elevated free homocystine is almost certainly indicative of a genetic disorder rather than a secondary hyperhomocysteinaemia. Also, the low / normal methionine level points to a remethylation disorder. Thus, labs not referring to methionine were penalised as were those suggesting only mild/moderate hyperhomocysteinaemia.

3.2.4. Best interpretation (scored with 2 points each)

- **Findings:** The free homocystine was clearly elevated, with a low-normal methionine concentration. Concentrations of some other amino acids were also low to low-normal, i.e., serine, leucine, glutamic acid, arginine, and isoleucine.
- Diagnosis: DD for hyperhomocystinaemia with low-normal methionine levels: MTHFR deficiency MS deficiency Defect in Cbl metabolism (Cbl C, D, E, F, G; transcobalamin def; Imerslund syndrome) Deficiency of folic acid or vit B12 (nutritional) Remark: Homocysteinaemia might also be the result of renal insufficiency
- Further tests: Further testing of urine organic acid looking for methylmalonic acid and urine metabolic screen analysis, check total homocysteine in blood, active B12 and folate levels; WES/WGS testing and referral to the metabolic clinic.

3.3. Case 2023-6: Glutaminase deficiency

3.3.1. Sample details

The results provided are from a 3-year-old girl with developmental delay. (Note: In the first request form only developmental delay was noted. In the first clinical letter following symptoms were mentioned: Severe global developmental delay, hypotonia, MRI brain scan shows non-specific delay in maturation of myelination, intermittent tremor, and ataxia. (See van Kuilenburg et al Glutaminase deficiency caused by short tandem repeat expansion in GLS. NEJM 2019)

3.3.2. Scoring details

 Table 3: Scoring details for case 2023-6.

	interpretation	nterpretation							
findings, abnormalities,	elevated	elevated gln							
maximum 2 points									
	glutaminase deficienc	2							
diagnosis, maximum 2 points	urea cycle disorder (bu	1							
	CAVA	1							
	organic acids		1						
further tests (if molecular	orotic acid		1						
genetic recommended specify	molecular genetic ana	2							
the gene), maximum 2 points	CSF glutamine		1						
	enzymatic analysis glu	1							

Scores for <u>participating</u> laboratories are in APPENDIX 1 on page 6.

3.3.3. Comments on overall performance

This was only moderately good for a rather difficult sample (overall performance 82%). In this case the follow up investigations are important especially in the absence of a correct diagnosis.

3.3.4. Best interpretation (scored with 2 points each)

- **Findings:** Elevated glutamine and mild elevation of several other amino acids including alanine, glycine, proline, threonine, lysine, serine, and arginine
- **Diagnosis:** Very high level of Glutamine with normal ammonia led us to suspect glutaminase deficiency. Pyruvate carboxylase deficiency it is less likely because citrulline and ammonia is normal. If the patient is on glutamine supplementation, exclude mitochondrial disease.
- **Further tests:** Measure organic acids incl. orotic acid in urine, which are normal in published cases of glutaminase deficiency. Also perform genetic analysis to check for a trinucleotide repeat expansion (CGA)n in the glutaminase gene. If negative, consider whole exome sequencing and extended metabolic screening.

3.4. Comments on the whole of the second circulation results 2023

Generally, the overall performance was good although a few labs made inadequate or incorrect interpretation leading to reduced scores. In some cases these were considered to be critical errors.


	2023.04				202	3.05		2023.06				2023.0406	
	Α	D	R	Sum	Α	D	R	Sum	Α	D	R	Sum	Totals
Total Points	254	254	246	754	233	241	245	719	254	170	203	627	2100
% proficiency	99%	99%	96%	98%	91%	94%	96%	94%	99%	66%	79%	82%	91%

Table 4: Overall scores for the second circulation in the amino acid interpretation scheme

Key

A = Findings, abnormalities

- D = Diagnosis
- R = Recommendations for further testing



DOC5149 Amino Acids Interpretation scheme 2023 Second Round Interim Report



Detailed scores for the second circulation in the Amino Acid Interpretation scheme

We encourage participants to send us comments and suggestions regarding this scheme and do not hesitate to contact us if you question any of our scoring.

Date: 19.12.2023

The Scientific Evaluators

Sabine Scholl-Bürgi, Scientific Advisor

Scheme Assessors: Brian Fowler, Rachel Carling, Mary Anne Preece, Daniela Karall, Apolline Imbard, Olivier Braissant, Alistair Horman, Anke Schuhmann

ERNDIM

APPENDIX 1. Detailed scores for submitting laboratories

<u>Key</u>

A = Findings, abnormalities

D = Diagnosis

R = Recommendations for further testing

Anon. Iab		202	23.04			202	23.05			202	23.06		2023.0406
number	Α	D	R	Sum	Α	D	R	Sum	Α	D	R	Sum	Total Score
1	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	2.0	2.0	6.0	17.0
2	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
3	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
4	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	17.0
5	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
6	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
7	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	17.0
8	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
9	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	2.0	4.0	16.0
10	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	17.0
11	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
12	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
13													
14	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
15	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
16	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	17.0
17	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	2.0	2.0	6.0	17.0
18	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
19	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	2.0	4.0	16.0
20	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
21	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
22	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
23	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
24	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
25	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	2.0	2.0	2.0	6.0	16.0
26	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
27	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
28	2.0	2.0	2.0	6.0	1.0	1.0	2.0	4.0	2.0	0.0	1.0	3.0	13.0
29	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
30	2.0	1.0	1.0	4.0	0.0	0.0	0.0	0.0	2.0	0.0	1.0	3.0	7.0
31	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
32	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
33	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
34	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
35													
36	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
37	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
38	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
39	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	2.0	2.0	6.0	17.0



Anon.		202	23.04			202	23.05			202	23.06		2023.0406
lab	•	_	_	C	•		_	C	•			C	
number 40	A 2.0	D 2.0	R 2.0	Sum 6.0	A 1.0	D 2.0	R 2.0	Sum 5.0	A 2.0	D 0.0	R 2.0	Sum 4.0	Total Score 15.0
41	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
41	2.0	2.0	1.0	5.0	2.0	1.0	2.0	5.0	2.0	0.0	1.0	3.0	13.0
42	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
44	2.0	2.0	2.0	0.0	2.0	2.0	2.0	0.0	2.0	2.0	2.0	0.0	10.0
44	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
45	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
40	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	3.0	15.0
47		2.0			-	2.0	2.0		2.0		-		
48	2.0 2.0	2.0	2.0 2.0	6.0 6.0	2.0 2.0	2.0	2.0	6.0 6.0	2.0	2.0 2.0	2.0 2.0	6.0 6.0	18.0 18.0
49 50	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
50	2.0	2.0			-	2.0			-	2.0	-		
-		-	2.0	6.0	1.0		2.0	5.0	2.0		2.0	6.0	17.0
52	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	1.0	0.0	3.0	14.0
53	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
54	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.0
55	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
56	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
57	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
58	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	1.0	1.0	4.0	15.0
59	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
60	2.0	2.0	2.0	6.0	1.0	1.0	2.0	4.0	2.0	2.0	2.0	6.0	16.0
61	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
62	2.0	2.0	1.0	5.0	1.0	1.0	1.0	3.0	2.0	0.0	1.0	3.0	11.0
63	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
64 65	0.0 2.0	2.0 2.0	2.0	4.0	1.0 2.0	2.0 2.0	0.0	3.0	2.0	2.0 2.0	2.0 2.0	6.0	13.0
66		-	2.0	6.0	-		2.0	6.0	2.0	-	_	6.0	18.0 17.0
67	2.0 2.0	2.0 2.0	2.0	6.0 6.0	1.0	2.0 2.0	2.0 2.0	5.0	2.0 2.0	2.0 2.0	2.0 2.0	6.0 6.0	
68	2.0	2.0	2.0 2.0	6.0	2.0 2.0	2.0	2.0	6.0 6.0	2.0	2.0	2.0	2.0	18.0 14.0
69	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	14.0
70	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
70	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
72	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
72	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	4.0 6.0	18.0
73	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	2.0	2.0	2.0	6.0	17.0
74	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
75	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
70	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
78	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
78	2.0	2.0	2.0	5.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	15.0
80	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
81	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
82	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
83	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
84	2.0	2.0	2.0	0.0	2.0	2.0	2.0	0.0	2.0	2.0	2.0	0.0	10.0
04													



Anon.		202	23.04			202	23.05			202	23.06		2023.0406
lab number	Α	D	R	Sum	Α	D	R	Sum	Α	D	R	Sum	Total Score
85	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
86	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
87	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
88	2.0	2.0	1.0	5.0	1.0	0.0	1.0	2.0	2.0	1.0	0.0	3.0	10.0
89	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
90	2.0	2.0	2.0	6.0	2.0	0.0	0.0	2.0	2.0	0.0	1.0	3.0	11.0
91	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
92	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	0.0	2.0	14.0
93													
94	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
95	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	2.0	0.0	1.0	3.0	14.0
96	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	1.0	5.0	17.0
97	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
98	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
99	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
100	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
101	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
102	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
103	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	17.0
104	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
105	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	0.0	1.0	1.0	2.0	14.0
106	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
107	2.0	1.0	1.0	4.0	2.0	2.0	2.0	6.0	2.0	0.0	0.0	2.0	12.0
108	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	2.0	5.0	17.0
109	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
110	2.0	2.0	0.0	4.0	2.0	2.0	2.0	6.0	2.0	0.0	0.0	2.0	12.0
111	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
112	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
113	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
114	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	2.0	2.0	6.0	17.0
115	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	2.0	2.0	6.0	17.0
116	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
117	2.0	2.0	2.0	6.0	1.0	1.0	1.0	3.0	2.0	2.0	2.0	6.0	15.0
118	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
119	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	0.0	1.0	3.0	14.0
120	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
121	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
122	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
123	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
124	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
125	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
126	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	1.0	3.0	15.0
127	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
128	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	0.0	1.0	3.0	14.0
129	2.0	2.0	1.0	5.0	1.0	2.0	2.0	5.0	2.0	0.0	1.0	3.0	13.0



Anon. Iab		202	23.04			202	23.05			202	23.06	2023.0406	
number	Α	D	R	Sum	Α	D	R	Sum	Α	D	R	Sum	Total Score
130	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	18.0
131	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	1.0	1.0	4.0	16.0
132	2.0	2.0	1.0	5.0	1.0	1.0	1.0	3.0	2.0	0.0	0.0	2.0	10.0
133	2.0	2.0	2.0	6.0	2.0	2.0	2.0	6.0	2.0	0.0	0.0	2.0	14.0
134	2.0	2.0	2.0	6.0	1.0	2.0	2.0	5.0	2.0	0.0	1.0	3.0	14.0
135													

APPENDIX 2. Change log (changes since the last version)

Version Number	Published	Amendments
1	21 December 2023	2023 second round interim report published

END OF REPORT